Outcomes of Everolimus plus Exemestane in ER-positive, HER2-negative Heavily Pre-treated Metastatic Breast Cancer Patients: A Real Life Multicentre Experience

被引：0
|
作者：
Desai, P. [1 ]
Hogg, M. [2 ]
机构：
[1] Royal Preston Hosp, Preston, Lancs, England
[2] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England
来源：
CLINICAL ONCOLOGY | 2018年 / 30卷 / 06期
关键词：
D O I：
10.1016/j.clon.2018.02.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E42 / E43
页数：5
相关论文
共 50 条
  • [31] Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
    Matikas, Alexios
    Foukakis, Theodoros
    Michalakis, Ilias
    Georgoulias, Vassilis
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) : 319 - 326
  • [32] New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (06) : 356 - 358
  • [33] Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
    Pascual, Javier
    Gil-Gil, Miguel
    Proszek, Paula
    Zielinski, Christoph
    Reay, Alistair
    Ruiz-Borrego, Manuel
    Cutts, Rosalind
    Ciruelos Gil, Eva M.
    Feber, Andrew
    Munoz-Mateu, Montserrat
    Swift, Claire
    Bermejo, Begona
    Herranz, Jesus
    Margeli Vila, Mireia
    Anton, Antonio
    Kahan, Zsuzsanna
    Csoeszi, Tibor
    Liu, Yuan
    Fernandez-Garcia, Daniel
    Garcia-Murillas, Isaac
    Hubank, Michael
    Turner, Nicholas C.
    Martin, Miguel
    CLINICAL CANCER RESEARCH, 2023, 29 (20) : 4166 - 4177
  • [34] Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer
    da Silva, Leonardo Roberto
    de Andrade, Camila Annicchino
    Brenelli, Fabricio
    Ramalho, Susana
    Reinert, Tomas
    de Souza, Alessandra Borba Anton
    da Silva, Ana Elisa Ribeiro
    de Paula Leite Kraft, Maria Beatriz
    de Vasconcelos, Vivian Castro Antunes
    Frasson, Antonio Luiz
    Torresan, Renato Zochio
    Cabello, Cesar
    Ellis, Matthew J.
    Zeferino, Luiz Carlos
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 753 - 760
  • [35] Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer
    Leonardo Roberto da Silva
    Camila Annicchino de Andrade
    Fabrício Brenelli
    Susana Ramalho
    Tomás Reinert
    Alessandra Borba Anton de Souza
    Ana Elisa Ribeiro da Silva
    Maria Beatriz de Paula Leite Kraft
    Vivian Castro Antunes de Vasconcelos
    Antônio Luiz Frasson
    Renato Zochio Torresan
    Cesar Cabello
    Matthew J. Ellis
    Luiz Carlos Zeferino
    Breast Cancer Research and Treatment, 2021, 186 : 753 - 760
  • [36] Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
    Shimoi, Tatsunori
    Shimomura, Akihiko
    Shien, Tadahiko
    Uemura, Yukari
    Kato, Hiroaki
    Kitada, Masahiro
    Toyama, Tatsuya
    Aihara, Tomohiko
    Mukai, Hirofumi
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2018, 10 : 13 - 18
  • [37] Real-world efficacy and safety of palbociclib combined with fulvestrant in japanese patients with ER-positive HER2-negative advanced or metastatic breast cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Shimizu, Ken
    Higeta, Kaori
    CANCER RESEARCH, 2020, 80 (04)
  • [38] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
    Rozenblit, Mariya
    Mun, Sophia
    Soulos, Pamela
    Adelson, Kerin
    Pusztai, Lajos
    Mougalian, Sarah
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [39] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
    Ottestad, Lars
    Fronth, Line
    Rajendiran, Sajitha
    Aksnes, Liv Hege
    Eikesdal, Hans Petter
    Blix, Egil Store
    Ewertz, Marianne
    ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
  • [40] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
    Mariya Rozenblit
    Sophia Mun
    Pamela Soulos
    Kerin Adelson
    Lajos Pusztai
    Sarah Mougalian
    Breast Cancer Research, 23
12345